Aeterna Zentaris Inc (NASDAQ:AEZS)

CAPS Rating: 5 out of 5

A growing global biopharmaceutical company focused on endrocrine therapy and oncology, in drug discovery, development and commercialization.

Recs

0
Player Avatar TMFBlacknGold (98.45) Submitted: 1/29/2013 3:36:19 PM : Underperform Start Price: $3.25 AEZS Score: +6.74

Investors must be confusing this company's past relationship with Keryx with the unrelated Zerenex data. Does it get any easier?

Featured Broker Partners


Advertisement